Effects of triple pharmacological therapy on post-discharge outcomes in patients with COPD

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)

  Safety study (incl. comparative)
• Data collection methods:
  Secondary use of data

Population studied

• Short description of the study population:
  Inclusion Criteria:; Spirometry-confirmed COPD diagnosis (post-bronchodilator FEV1/FVC <0.7 within one year before enrollment).; Age 40 years.; Smoking history of 10 pack-years.; Recent discharge from the hospital due to a severe exacerbation.; Patients receiving any therapy (mono-, duo-, triple therapy, or no therapy).; ; Exclusion Criteria:; Life expectancy shorter than six months.; Presence of concomitant chronic respiratory conditions, such as current asthma, severe bronchiectasis, cystic fibrosis, lung fibrosis, or active tuberculosis.; Severe comorbidities likely to limit survival to less than six months (e.g., active neoplasm or severe cardiac insufficiency).

Study design details

• Study design:
  An international, multicentre, retrospective database study
• Main study objective:
  to identify patients at the highest risk of hospital readmission, with a specific focus on evaluating the risk/benefit ratio of triple therapy on an individual basis. By addressing these objectives, the study aims to contribute to the development of targeted strategies for improving patient outcomes and optimising resource utilisation.;